Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491340 | 1.00 | TP53 (0.46) | TP53SMN1; SMN2HDAC1MAPKAPK2MAPT | |
| SCHEMBL12673048 | 0.93 | MAPKAPK2 (0.47) | TP53SMN1; SMN2HDAC1MAPKAPK2MAPT | |
| SCHEMBL1491489 | 0.91 | MAPKAPK2 (0.47) | TP53SMN1; SMN2HDAC1MAPKAPK2MAPT | |
| SCHEMBL1491493 | 0.91 | MAPKAPK2 (0.47) | TP53SMN1; SMN2HDAC1MAPKAPK2MAPT | |
| SCHEMBL1491400 | 0.90 | HDAC1 (0.48) | TP53HDAC1MAPTLMNAABCG2 | |
| SCHEMBL1491403 | 0.90 | HDAC1 (0.48) | TP53HDAC1MAPTLMNAABCG2 | |
| SCHEMBL14930036 | 0.85 | HDAC1 (0.51) | TP53HDAC1LMNAABCG2 | |
| SCHEMBL1491430 | 0.80 | HDAC1 (0.54) | TP53HDAC1MAPTLMNAABCG2 | |
| SCHEMBL1491428 | 0.80 | HDAC1 (0.54) | TP53HDAC1MAPTLMNAABCG2 | |
| SCHEMBL1493521 | 0.80 | HDAC1 (0.47) | TP53HDAC1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| US-7939666-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-05-10 | — | — | US | disclosed |
| EP-2301939-A1 | Enzyme inhibitors | Chroma Therapeutics Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20090291978-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-11-26 | — | — | US | disclosed |
| EP-1879895-A1 | ENZYME INHIBITORS | Chroma Therapeutics Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117549-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | TP53 342/4885SMN1; SMN2 3591/4885HDAC1 1/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | TP53 1898/4885SMN1; SMN2 3264/4885HDAC1 5/4885 |
| US-20090291978-A1 | Enzyme Inhibitors | HAT1, NR2E1, NR2C2 | TP53 2646/4885SMN1; SMN2 3848/4885HDAC1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.